Posted by Michael Wonder on 08 Jan 2020
Abuses of FDA regulatory procedures - the case of Suboxone
8 January 2020 - The manufacturer of brand-name buprenorphine products exploited various FDA regulatory procedures to impede market entry of generic competitors and to maintain high prices.
This case provides an example of the kinds of abuses that are common in prescription-drug markets.
